Saturday’s Midday Movers: Illumina (ILMN), Civeo (CVEO), Nu Skin (NUS), Inovio Pharmaceuticals (INO), Organovo Holdings (ONVO)

So far Saturday, February 13, NASDAQ is up 3.17% and the S&P is up 2.88%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Illumina (ILMNResearch Report), Civeo (CVEOResearch Report), Nu Skin (NUSResearch Report), Inovio Pharmaceuticals (INOResearch Report) and Organovo Holdings (ONVOResearch Report).

Illumina is up 11.35% in midday trading to $504.76. Shares opened today at $453.31. The company has a 52-week low of $196.78 and a 52-week high of $555.77. On the Street’s front, the average 12-month analyst price target for the stock is $417.22, marking a -7.96% potential downside from current levels. In a report released yesterday, Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on ILMN, with a price target of $445.00, which represents a slight downside potential from current levels. Separately, on the same day, Piper Sandler’s Steven Mah maintained a Buy rating on the stock and has a price target of $510.00.

Civeo is up 9.03% in midday trading to $20.40. Shares opened today at $18.71. The company has a 52-week low of $4.08 and a 52-week high of $20.55. On the Street’s front, the average 12-month analyst price target for the stock is $19.00, marking a 1.55% potential upside from current levels. In a report issued on December 18, RBC analyst Kurt Hallead maintained a Hold rating on CVEO, with a price target of $19.00, which represents a slight upside potential from current levels. Over the last 3 months, the insider sentiment on Civeo has been negative based on 27 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Nu Skin is down -8.27% in midday trading to $48.81. Shares opened today at $53.21. The company has a 52-week low of $12.31 and a 52-week high of $63.85. On the Street’s front, the average 12-month analyst price target for the stock is $62.00, marking a 16.52% potential upside from current levels. In a report released yesterday, D.A. Davidson analyst Linda Bolton Weiser downgraded NUS to Hold, with a price target of $58.00, which implies an upside of 9% from current levels. Separately, on February 2, Jefferies Co.’s Stephanie Wissink reiterated a Buy rating on the stock and has a price target of $66.00. Over the last 3 months, the insider sentiment on Nu Skin has been negative based on 45 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Inovio Pharmaceuticals is down -7.78% in midday trading to $14.22. Shares opened today at $15.42. The company has a 52-week low of $3.29 and a 52-week high of $33.79. On the Street’s front, the average 12-month analyst price target for the stock is $16.14, marking a 4.67% potential upside from current levels. In a report issued on February 11, Oppenheimer analyst Hartaj Singh initiated coverage with a Buy rating on INO and a price target of $35.00, which implies an upside of 127% from current levels. Separately, on January 7, H.C. Wainwright’s Ram Selvaraju reiterated a Hold rating on the stock .

Organovo Holdings is down -7.75% in midday trading to $19.39. Shares opened today at $21.02. The company has a 52-week low of $3.87 and a 52-week high of $23.92.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.